– UK, London – Mereo BioPharma Group plc (NASDAQ: MREO | LON: MPH), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Pierre Jacquet (M.D., Ph.D.) to its Board of Directors, effective September 20, 2021, adding two decades of multidisciplinary experience in the life science industry, including corporate strategy, M&A advisory and value management to the Board.
“We are delighted to have Pierre joining our board of directors at such an exciting and important time for the Company,” said CEO, Dr. Denise Scots-Knight. “Pierre’s twenty plus years as one of the top advisors in our industry will prove invaluable for Mereo as we continue to advance the clinical development of our portfolio. We very much look forward to his guidance as we continue our goal of treating patients in areas of high unmet medical need.”
The Company also announced that Peter Bains will retire from the Board of Directors after serving as a board member for over 6 years including as a member of the R&D Committee, former Chairman of the Remuneration Committee, and as an advisor before the Company’s formation.
About Dr. Pierre Jacquet
Dr. Jacquet is currently Managing Director and Vice Chairman of L.E.K. Consulting’s Healthcare practice. He has served in a variety of leadership roles over 20 years at L.E.K., including Global Head, Healthcare Practice, Global Leadership Team, the Americas management committee, and various partner operating committees. Before joining L.E.K. in 2001, Dr. Jacquet was trained as a surgical resident at the University of Liège, Belgium, and served as a Fellow at the Washington Cancer Institute, where he authored over 40 publications and presentations. In addition to serving on Mereo’s Board of Directors, Dr. Jacquet is a Director of Exact Sciences, on the Advisory Board of Life Science Cares, and previously served as a Director of Osprey Pharmaceuticals. He earned a Master of Business Administration from the Darden Graduate School at the University of Virginia, graduated Magna Cum Laude in Medicine from the University of Liège in Belgium and was awarded a Summa Cum Laude Doctor of Philosophy in biomedical sciences from the University of Liège in Belgium.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. The Company has developed a portfolio of six clinical-stage product candidates. Mereo’s lead oncology product candidate, etigilimab (Anti-TIGIT), has recently advanced into an open label Phase 1b/2 basket study evaluating Anti-TIGIT in combination with an anti-PD-1 in a range of tumor types including three rare tumors and a number of gynecological carcinomas including cervical, ovarian and endometrial carcinomas. The Company’s second oncology product, navicixizumab, for the treatment of late line ovarian cancer, has completed a Phase 1 study and has been partnered with OncXerna Therapeutics, Inc., formerly Oncologie, Inc. The Company has two rare disease product candidates: alvelestat for the treatment of severe Alpha-1 antitrypsin deficiency, which is being investigated in an ongoing Phase 2 proof-of-concept study in the U.S. and Europe, for which the Company expects to report on in late 2021, and setrusumab for the treatment of osteogenesis imperfecta (OI). In September 2020, the FDA granted Rare Pediatric Disease designation to setrusumab for the treatment of OI. In December 2020, the Company signed a license and collaboration agreement for setrusumab in OI with Ultragenyx Pharmaceutical Inc.
For more information : https://www.mereobiopharma.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
